Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics,

Slides:



Advertisements
Similar presentations
Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.
Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.
Co-supervisor: Prof Richard Lock
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
Antibody and prodrug therapy of cancer
BIOL 445 – CANCER BIOLOGY PRESENTATION
RA190 Small Molecule Proteasome Inhibitor for Cancer Therapy.
Differential activity of synthetic Au (III) and Pt (II) diethyldithiocarbamate complexes towards the proteasome in hepatoma cell line SK-Hep1 INTRODUCTION.
Vice President, Cancer Therapeutics, Inc.
Necitumumab Drugbank ID :DB09559 Molecular Weight (Daltons) :144800
Development of novel therapeutic agents for neuroblastoma through iron and cholesterol metabolisms study Sang Y. Lee, Ph.D. Assistant Professor Department.
Cancer When good cells go bad.
ID DB08935 OBINUTUZUMAB C6512H10060N1712O2020S kDa CATEGORY
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Nivolumab Drugbank ID : DB09035 Molecular Weight (Daltons) :
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
The Mammosphere- Use of 3D tumor models to study Breast Cancer
A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich 
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
…driving discovery An improved potent direct thrombin inhibitor shows efficacy with low bleeding risk Anirban Datta et al.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Inhibitor of MAP kinase activation blocks colon cancer growth
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Volume 5, Issue 2, Pages (August 2009)
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation  Lily Mahapatra, Neal Andruska, Chengjian Mao,
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
HSF1 in Translation Cancer Cell
M.H. Li, R. Xiao, J.B. Li, Q. Zhu  Osteoarthritis and Cartilage 
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Daniel Abate-Daga, Marco L Davila  Molecular Therapy - Oncolytics 
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Volume 131, Issue 5, Pages (November 2006)
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Volume 131, Issue 5, Pages (November 2006)
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models  Josephine Hai, PhD, Shingo Sakashita,
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
ID Proteins Regulate Diverse Aspects of Cancer Progression and Provide Novel Therapeutic Opportunities  Radhika Nair, Wee Siang Teo, Vivek Mittal, Alexander.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich 
Molecular Therapy - Nucleic Acids
Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.
Jae Won Chang, Daniel K. Nomura, Benjamin F. Cravatt 
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Abebe Genetu Bayih, PhD University of Gondar
Cancer Treatment.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Volume 16, Issue 12, Pages (December 2008)
Volume 2, Issue 2, Pages (August 2002)
Simplified BRAF signaling network.
MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.
Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics, University of Virginia Jeff James Licensing Manager UVA Licensing and Ventures Group

Value position Novel small molecule inhibitors that are potent against breast, ovarian, and lung epithelial cancer cell lines and use a les exploited mechanism by targeting a transcription factor involved in cancer pathways Transcription factor inhibition as treatment mechanism Potent against epithelial cancer cell lines in vitro Specific ablation of cancer cell and not normal cell lines in vitro Potential for targeting of cancer stem cells Compounds are orally bioavailability Potentially low toxicity Compounds target multiple cancer types

Market Respiratory Cancers: 67% mortality in US Market expected to grow from $4 billion in 2010 to $13.5 billion by 2020 Breast Cancers: 18% mortality in US Market expected to grow from $9.8 billion in 2013 to $18.2 billion by 2023 Ovarian Cancers: 67% mortality in US Market expected to grow from $460 million in 2011 to $1.4 billion by 2021 Current treatments utilize monoclonal antibodies or small molecule inhibitors Pitfalls: Off target effects, toxicity, moderately effective, most converge on small number of biological pathways and downstream effectors, e.g. EGFR, Ras, PI3K, Her2 There is the need for more potent therapies that address other pertinent pathways involved in breast, ovarian and lung cancer progression Source: World Cancer Research Fund, American Cancer Society, IMShealth, Markets&Markets, Decision Resources

Mechanism of action CBFβ and RUNX1 are proteins that together to form Core Binding Factor, a transcription factor involved in cellular development Compounds bind to CBFβ and block its interaction with RUNX proteins, abrogating downstream signaling events associated with cancer

Compounds Kill Epithelial Lung Cancer Cells but Not Normal Lung Cells A) Active inhibitor reduces lung cancer cell viability to similar degree as staurosporine, a well-defined inducer of cell death, compared to treatment with DMSO and inactive control. B) Active inhibitor has no deleterious effect on viability of normal lung cell line as compared to staurosporine treatment. B) AI-10-104 Active inhibitor AI-4-88 Inactive control

CBFβ Inhibitor Ablates Viability of Ovarian Cancer Cell Lines Dose-dependent effect of AI-10-104 inhibitor on ovarian cancer cell lines after 72 hours

Compounds are Effective Against Breast Cancer Cell lines in 3D Organotypic Culture A) Brightfield microscopy of colony breast cancer cell line colony forming units (CFU) in 3D culture B) Enumerated CFUs show active inhibitor reduces growth of cell line in 3D culture compared to control treatments. A) B) Active inhibitor (AI-14-91, AI-10-104) 1 µM Inactive control (AI-4-88) 1 µM AI-14-91 is a derivative of AI-10-104 with improved in vivo properties

CBFβ Inhibitors are Orally Bioavailable : Plasma concentration as a function of time for active inhibitors AI-12-126 or AI-14-91 : concentration from oral gavage dosing  : Concentration from intraperitoneal dosing (100 mg/kg) in mice.   AI-12-126 Intraperitoneal AI-14-91 Oral Gavage AI-14-91 Intraperitoneal Half life (min) 179 203 243 AUC(0-inf) (µmol∙min/L) 8.14 2.22 2.08 Mean Residence Time (min) 74.6 180.4 90.6 Volume of Distribution (mL) 193.9 754.0 958.7 Clearance (mL/min) 0.75 2.57 2.74

Future Work We’re continuing development of the compounds: Testing inhibitor efficacy in vivo, 6-8 months Optimizing compounds – 6-12 months Test toxicity of optimized compounds in vivo, 12-18 months UVa is currently searching for partners to continue developing these compounds as anti- tumor agents

UVa Licensing and Ventures Group Contact: Jeffrey A. James, Ph.D., CLP. Licensing Manager UVa Licensing and Ventures Group 722 Preston Ave., Ste. 107 Charlottesville, VA 22902 (434) 982-1608 (direct) (434) 924-2175 (main) (434) 982-1583 (fax) jeff.james@virginia.edu www.innovation.virginia.edu